Gilead and Second Genome Sign US$1.5 B Microbiome-based Drug Discovery Deal
By Sasha Yachu & Michelle Liu
Pharma Deals Review: Vol 2020 Issue 5 (Table of Contents)
Published: 8 May-2020
DOI: 10.3833/pdr.v2020.i5.2534 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In its first foray into the microbiome space, Gilead has agreed to partner with Second Genome to identify biomarkers and potential new drug targets in inflammation, fibrosis and other diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS